Rep. Waxman letter to Kessler
Executive Summary
California Democrat tells FDA commissioner in a September letter that he is "concerned" that FDA's Aug. 28 Federal Register notice soliciting comment on the proposed withdrawal of 116 pre- 1986 pending regulations does not contain enough information. Waxman said FDA should "describe the substance" of each reg to provide for public comment and argued that "it is not appropriate to withdraw a proposed rule simply because it is more than six years old and has not been designated 'high priority.'" Instead, each proposal should be considered independently, to be pursued if it has merit and withdrawn if it does not," Waxman wrote. The move to eliminate lingering regs was initiated by new Deputy Commissioner for Policy Michael Taylor ("The Pink Sheet" Sept. 2, p. 13)....
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth